Thema
610
10
Recruitment Status: Not yet recruiting
8
Study Type: Interventional
8
Phase: Phase 4
6
Medical Condition: Coronavirus disease 2019 (COVID-19) / SARS-CoV-2 Disease MedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestations MedDRA version: 23.1Level: PTClassification code 10084460Term: COVID-19 treatmentSystem Organ Class: 10042613 - Surgical and medical procedures MedDRA version: 23.0Level: LLTClassification code 10084270Term: SARS-CoV-2 acute respiratory diseaseSystem Organ Class: 10021881 - Infections and infestations MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 10021881 - Infections and infestations MedDRA version: 23.1Level: LLTClassification code 10084439Term: SARS-CoV-2 serology test positiveSystem Organ Class: 100000004848 MedDRA version: 21.1Level: LLTClassification code 10054540Term: Passive immunizationSystem Organ Class: 10042613 - Surgical and medical procedures;Therapeutic area: Diseases [C] - Virus Diseases [C02]
2
Medical Condition: For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC US) and cervical intraepithelial neoplasia (CIN), CIN 1 and pre-cancerous lesions (CIN 2 and CIN 3), caused by oncogenic HPV types 16 and 18. MedDRA version: 19.0Level: LLTClassification code 10071147Term: Human papilloma virus immunizationSystem Organ Class: 100000004865 MedDRA version: 19.0Level: LLTClassification code 10058580Term: Human papilloma virus serology testSystem Organ Class: 100000004848;Therapeutic area: Diseases [C] - Cancer [C04]
2
Medical Condition: Healthy volunteers [For active immunisation of females from 9 years of age onwards for the prevention of persistent infection, premalignant genital (cervical, vulvar and vaginal) lesions and cervical, vulvar and vaginal cancers (squamous-cell carcinoma and adenocarcinoma) caused by oncogenic Human Papillomaviruses (HPV)]. MedDRA version: 16.1Level: LLTClassification code 10071147Term: Human papilloma virus immunizationSystem Organ Class: 100000004865 MedDRA version: 16.1Level: LLTClassification code 10058580Term: Human papilloma virus serology testSystem Organ Class: 100000004848;Therapeutic area: Diseases [C] - Virus Diseases [C02]
2
Medical Condition: Serological testing of antibodies against SARS-CoV-2 and an analysis of differences between symptomatic and asymptomatic COVID19 courses.
2
Medical Condition: This study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate whether immunisation against infection with HPV 16 and 18 may impact on other oncogenic HPV types, through cross-protection. MedDRA version: 9.1 Level: LLT Classification code 10058580 Term: Human papilloma virus serology test
2
Phase: Phase 2
2
Recruitment Status: Recruiting
2
Study Type: Observational
2